Search Results for "success rates" | Oncology Voice Network

A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Apr 20^th • 7 mins read

Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23^rd • 8 mins read

Paulo J. Oliveira, Ana M. Urbano

“Oncometabolism: The switchboard of cancer: An editorial”

Feb 1^st • 1 min read

Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1^st • 4 mins read

Xuanyi Li, Elizabeth A. Sigworth, Adrianne H. Wu, Jess Behrens, Shervin A. Etemad, Seema Nagpal, Ronald S. Go, Kristin Wuichet, Eddy J. Chen, Samuel M. Rubinstein, Neeta K. Venepalli, Benjamin F. Tillman, Andrew J. Cowan, Martin W. Schoen, Andrew Malty, J

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Oct 16^th • 12 mins read

Ramez Kouzy , Joseph Abi Jaoude , Walker Mainwaring , Timothy A. Lin , Austin B. Miller , Amit Jethanandani , Andres F. Espinoza , Vivek Verma , Clifton D. Fuller , Bruce D. Minsky , Claus Rödel , Cullen M. Taniguchi , Ethan B. Ludmir

Professional Medical Writer Assistance in Oncology Clinical Trials

Sep 17^th • 7 mins read

Peter N Morcos, Junyi Li, Iraj Hosseini, Chi‐Chung Li

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities

Nov 18^th • 15 mins read

Jaques van Heerden, MD, Mohamed Zaghloul, MD, Anouk Neven, MSc, Teresa de Rojas, MD, PhD, Jennifer Geel, MD, Catherine Patte, MD, Joyce Balagadde-Kambugu, MD, Peter Hesseling, MD, Francine Tchintseme, MD, Eric Bouffet, MD, and Laila Hessissen, MD

Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives

Aug 7^th • 10 mins read

Mateusz T. Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora

Clinical development success rates and social value of pediatric Phase 1 trials in oncology

Jun 21^st • 28 mins read

Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Apr 1^st • 14 mins read

Tanja Cufer, Tudor E. Ciuleanu, Peter Berzinec, Gabriela Galffy, Marko Jakopovic, Jacek Jassem, Dragana Jovanovic, Zhasmina Mihaylova, Gyula Ostoros, Christiane Thallinger, Milada Zemanova, Christoph Zielinski

Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

Nov 24^th • 10 mins read

Benjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman

Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

Feb 17^th • 7 mins read

Jingjing Yu, Isabelle Ragueneau-Majlessi

In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018

Jan 25^th • 12 mins read

Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Jan 20^th • 20 mins read

Mythili Shastry, PhD, Avantika Gupta, PhD, Sarat Chandarlapaty, MD, PhD, Matthew Young, MD, Thomas Powles, MD, and Erika Hamilton, MD

Rise of Antibody-Drug Conjugates: The Present and Future

May 25^th • 20 mins read

Kenji Omae, Yuki Kataoka, Yasushi Tsujimoto, Yusuke Tsutsumi, Yosuke Yamamoto, Shunichi Fukuhara, Toshi A Furukawa

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Oct 24^th • 18 mins read

YuQian Liu, PharmD

Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems

Jul 7^th • 25 mins read

John Hair, Thomas Maryon, and Cristian Lieneck

Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption

Oct 27^th • 30 mins read

Envision Pharma Group

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9^th • 5 mins read